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ORIGINAL ARTICLE
The P2 promoter of the IGF1 gene is a major epigenetic locus
for GH responsiveness
M Ouni1, MP Belot1, AL Castell2, D Fradin1 and P Bougnères1,2
Short children using growth hormone (GH) to accelerate their growth respond to this treatment with a variable efﬁcacy. The causes
of this individual variability are multifactorial and could involve epigenetics. Quantifying the impact of epigenetic variation on
response to treatments is an emerging challenge. Here we show that methylation of a cluster of CGs located within the P2
promoter of the insulin-like growth factor 1 (IGF1) gene, notably CG-137, is inversely closely correlated with the response of growth
and circulating IGF1 to GH administration. For example, variability in CG-137 methylation contributes 25% to variance of growth
response to GH. Methylation of CGs in the P2 promoter is negatively associated with the increased transcriptional activity of P2
promoter in patients' mononuclear blood cells following GH administration. Our observation indicates that epigenetics is a major
determinant of GH signaling (physiology) and of individual responsiveness to GH treatment (pharmacoepigenetics).
The Pharmacogenomics Journal advance online publication, 14 April 2015; doi:10.1038/tpj.2015.26
INTRODUCTION
Tens of thousands of children affected by various causes of short
stature currently receive recombinant growth hormone (GH) to
improve their ﬁnal height. However, the high variability of
individual GH responsiveness results in unequal growth improve-
ment. The large individual variability of the therapeutic response
to GH has puzzled pediatric endocrinologists for decades. The
causes underlying such variability have until now been searched
in the aetiologies of short stature, treatment regimens, patients’
compliance1 and genetic polymorphisms.2 This individual varia-
tion is partly due to the variable insulin-like growth factor 1 (IGF1)
production under GH treatment, reﬂected by circulating IGF1
concentration,3 thus serum IGF1 measurement can be used to
adjust GH dosage in treated children.3 Despite its importance to
therapeutics, the variation of GH responsiveness across treated
patients has prompted few studies in search of biological
mechanisms.4 The increment in growth rate induced by GH
treatment in healthy children with ‘idiopathic’ short stature is
normally distributed and can thus be modeled as a continuous
quantitative trait. Genetic factors certainly have a role.4 Notably,
the deletion of exon 3 within the GH receptor (GHRd3) gene has
been recognized as a signiﬁcant pharmacogenetic predictor of GH
growth-promoting effects in children with idiopathic short
stature.2 Children carrying GHRd3 also show higher circulating
IGF1 in response to GH injection.5 Despite this ﬁrst advance, the
variability of GH responsiveness in children with ‘idiopathic’ short
stature has yet received limited molecular explanation.
Pharmacoepigenomics is a nascent ﬁeld of clinical medicine
that holds many promises, but has not yet produced tangible
results.6 The methylation of the cytosine within CG dinucleotides
is the simplest component of DNA epigenetics that can be studied
in patients receiving a treatment. Among the millions of CG
residues in the human genome sequence, a yet unknown number
of regions were found to show individual variation of CG
methylation in a given cell population. These regions contain CG
residues that are expected to contribute to the individual
variability of human phenotypes, provided that such CGs are
signiﬁcantly involved in the regulation of neighboring gene
transcription. In many experimental studies, the methylation of CG
residues located within low CG-rich promoters has been
recognized as a potentially major factor for gene regulation.7
To explore the epigenetic component of the individual
variability of growth and circulating IGF1 responses to treatment
with GH, we thought there was no better physiological candidate
than the IGF1 gene, a key player in postnatal growth, and GH
signaling. Inactivating mutations in IGF1 alter postnatal growth in
humans8 and mice.9 In contrast, common genetic variation in IGF1
gene does not contribute signiﬁcantly to adult height variation in
Caucasians10 but do so in Asians11 in whom minor allele frequency
is greater. Estimates of the proportion of variance in circulating
IGF1 that is genetically determined vary between 38% and480%
according to twin studies.12 The association of circulating IGF1
with several genetic variants is debated,13 but variants at the
IGF1 locus do not seem to inﬂuence circulating IGF1 levels in
Caucasians.13
Our working hypothesis was that epigenetic marks located in
regulatory regions might have a role in modulating IGF1 gene
expression, as observed for many genes, and could therefore
contribute to the individual variation of IGF1 production and
child’s growth. We therefore focused on the two promoters that
are directly involved in the regulation of IGF1 gene expression14
and are CG-poor promoters expected to exhibit inter-individual
variation.15 The choice of a candidate gene approach instead of
commercially available arrays made us able to quantify the
methylation of each CG of the IGF1 promoters. Indeed, individual
CG may have a signiﬁcant functional role possibly different from
its CG neighbors. GH has been shown to directly stimulate
transcription of the IGF1 gene in rats and mice.16,17 GH exerts its
effects through the JAK/Stat pathway with translocation of
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activated Stat5b transcription factor to the nucleus where it
regulates IGF1 transcription.18 GH-induced transcription promotes
accumulation of all classes of IGF1 mRNA.16,17,19 Class 1 transcripts
have their initiation sites on exon 1 and are driven by P1
promoter, whereas class 2 transcripts use exon 2 as a leader exon
(P2) and are driven by P2 promoter.20,21
In growing children, GH responsiveness is important to both
physiology and therapeutics. To explore the relation between IGF1
promoter methylation and response to GH in growing children,
we selected children who have not entered puberty to avoid the
confounding effect of the variable tempo of sexual maturation,
which adds to the variability of growth and circulating IGF1. We
used the long-studied ‘generation test’5 to test the direct effect of
GH on circulating IGF1 and transcription of IGF1 gene in blood
cells of 40 children with idiopathic short stature yet naive to GH
treatment. Whether P2 CG methylation could inﬂuence the
therapeutic efﬁcacy of GH was our next question. To study
whether the therapeutic response to GH differs across the various
levels of promoter P2 methylation, 136 children with so called
‘idiopathic’ short stature were studied during their ﬁrst year of GH
administration for both increment in growth rate and in
circulating IGF1.
MATERIALS AND METHODS
Participants
136 children who had varying degrees of ‘idiopathic short stature’ were
treated with recombinant GH (Table 1). All of them were healthy, had
normal clinical examination and no signs of puberty (girls showed no
breast development and boys had unmeasurable testosterone levels). GH
deﬁciency was excluded with a stimulated GH peak 415 ngml− 1. All
subjects had normal TSH levels. Subtle chondrodysplasia were excluded by
forearm, pelvis and spine radiographs. Trained nurses performed height
measurements in duplicate using the Harpenden stadiometer. Blood
samples were obtained before onset of GH treatment. We did not carry out
this study using GH deﬁcient children because the causes for this
deﬁciency are highly heterogeneous (mutations of pituitary transcription
factors, irradiation for cancer, hypothalamic tumors and so on) and are
often associated with other hormone deﬁcits or medical problems.
At onset of treatment, an acute test was performed by injecting
100 μg kg− 1 of recombinant GH intramuscularly to 40 children and
sampling blood before and 12 h after the injection. Thereafter, children
were all followed by a pediatric endocrinologist for the management of GH
treatment. Height (Harpenden stadiometer) and serum IGF1 measure-
ments were performed at 6, 9 and 12 months of treatment.
For methylation and transcript measurements, 10 ml peripheral blood
samples were obtained, from which white blood cells and/or PBMC
(peripheral blood mononuclear cells) were puriﬁed immediately. White and
mononuclear cell were counted at the time of sampling. For measuring
transcripts, PBMC were collected at the clinical center close to the
laboratory and mRNA was extracted immediately.
Parents of all studied children gave their written informed consent for
the current study and for using surgical specimens, according to the
French rules of bioethics in biomedical research checked by our
Institutional Review Board.
Serum IGF1 concentrations
Serum IGF1 concentration was measured around 0700 to 0800 hours
before breakfast in 136 children using an immune-radiometric assay after
ethanol-acid extraction using DSL-5600 Active (Diagnostic System
Laboratories, Webster, TX, USA) or Cisbio reagents. Intra- and inter-series
coefﬁcients of variation were 1.5% and 3.7% at 260 ngml− 1 and 3.9% at
760 ngml− 1. The sensitivity was 4 ngml− 1. IGF1 SDS were calculated using
the norms of Alberti et al.22 in French children.
DNA methylation at CpG resolution in IGF1 promoters 1 and 2
For promoter P1, we studied nine CGs located over a 800 bp distance, the
closest CG being 225 bp upstream from the corresponding major
transcription start site23 (Figure 1). For promoter P2, we studied 7/8 CGs
located upstream from the major transcription start site within the
proximal part of the promoter and one CG located 97 bp downstream this
transcription start site (Figure 1). CGs are denominated according to their
position versus each promoter transcription start site. The methylation of
CG-22 could not be measured for technical reasons. Nucleic acids were
extracted from white blood cells or PBMC using Gentra Puregene blood kit
(Qiagen, Hilden, Germany). A bisulﬁte-PCR-pyrosequencing technique24
was used to measure the methylation of the CGs. We improved the
resolution of this method from a handful of bases to up to 100 nucleotides,
with the ability to quantify methylation in the same sample of blood with a
coefﬁcient of variation (s.d./mean) as little as 1–5%. Brieﬂy, 400 ng of
genomic DNA were treated with EZ DNA Methylation-Gold Kit, according
to manufacturer’s protocol (Zymo Research Corporation, CA, USA). The
bisulﬁte-treated genomic DNA was PCR-ampliﬁed using unbiased IGF1
primers (Supplementary Methods Table 1) and performed quantitative
pyrosequencing using a PyroMark Q96 ID Pyrosequencing instru-
ment (Qiagen). Pyrosequencing assays were designed using MethPrimer
(http://www.urogene.org/methprimer/index1.html). Biotin-labeled single
stranded amplicons were isolated according to protocol using the Qiagen
Pyromark Q96 Work Station and underwent pyrosequencing with 0.5 μM
primer. The percent methylation for each of the CGs within the target
sequence was calculated using PyroQ CpG Software (Qiagen).
Study of IGF1 transcripts in PBMC
Methods are detailed in Supplementary Methods Table 2.
Calculations and statistical methods
IGF1 levels and height were expressed as SDS to adjust for age and sex.
The growth rate response to GH administration was expressed as
increment in growth rate, the difference between growth rate during GH
treatment (in cm per year) and previous growth rate (evaluated during the
whole year before onset of GH administration). We chose this quantitative
criterion because spontaneous growth in children with idiopathic short
stature is linear during this period of childhood. Correlations were
calculated as adjusted R square that measures the proportion of the
variation in the dependent variable accounted for by the explanatory
variables. The fraction of explained variance is calculated under the linear
regression model, using the usual deﬁnition: r2 × 100. We ﬁtted a
multivariate linear model to the data to estimate the proper effect of CG
methylation on response to GH, adjusted for the effect of the other
covariates contributing to the growth under treatment, such as age at
diagnosis, sex and the received dose of GH. This approach is suitable for
estimating the association between the variable of interest, here the
methylation level, and the trait in the presence of correlation between the
covariates. We carried out tests of independence of each covariate one at a
time, keeping the others in the model. Statistics and estimations of effect
given in the tables are thus adjusted for the others whenever appropriate
and are not subject to marginal association. We checked the normality of
the residuals, and the residuals versus the ﬁtted values did not show any
trend, indicating that there was no noticeable deviation from the
assumption of the linear model. All statistics and linear model were
computed using R 2.10.1. Results are expressed as mean± s.d.
Table 1. Main baseline characteristics of the studied children.
Acute GH
Injection test
GH-treated
Children
N 40 136
Sex (M/F) 27/13 72/64
Age (years) 10.8± 1.8 8.6± 3
Height (SDS) − 1.8± 0.7 − 2.2± 0.7
Growth rate before GH (SDS) − 1.3± 1.2 − 1.3± 1.2
Serum IGF 1 before GH (SDS) − 1.2± 0.8 − 1.3± 1
rhGH treatment dose
(mg kg− 1 per week)
— 0.47± 0.12
Growth rate at 1 year GH (SDS) — 4.6± 1.9
Serum IGF 1 at 1 year GH (SDS) — 0.6± 1.5
Abbreviations: F, female; GH, growth hormone; IGF1, insulin-like growth
factor 1; M, male; SDS, standard deviation score.
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RESULTS
Relationship between CG methylation and response of circulating
IGF1 and IGF1 transcripts to a ﬁrst GH injection
The methylation levels for the CGs located within the two
promoters of IGF1 is given in Supplementary Table S1.
Following the acute injection of GH, the increase in circulating
IGF1 was inversely related with CG-137 methylation (P= 3× 10− 7),
which accounted for as much as ~ 49% of the variability of this
increase (Figure 2a and Supplementary Table 2) and with the
methylation of 3/8 other P2 CGs (Figure 1 and Supplementary
Table 2).
In order to test whether methylation at the P2 promoter affects
the transcriptional response of the IGF1 gene to GH, we measured
P1-driven, P2-driven and total IGF1 transcripts in PBMC before and
12 h after the GH injection. We found a variable increase in IGF1
transcripts across the studied children. The increase in P2-driven
transcripts showed a very strong inverse correlation with CG-137
methylation (P= 5× 10− 11; Figure 2b) and with 4/8 other P2 CGs
(Supplementary Table 3). Among the CGs of P1 promoter, only
CG-611 showed an inverse correlation with P1-driven transcripts
(Supplementary Table 3). Methylation was unchanged by this brief
exposition to GH (not shown). We were not able to assess direct
GH effects on cultured PBMC from the patients, because when
these cells are submitted to short culture conditions, they show an
unreliable response of IGF1 expression to stimulation by GH.
IGF1 and growth response to GH treatment
As expected, GH-induced growth responses were variable, closely
ﬁtting the normal distribution (Supplementary Figure 1a) and
were correlated with circulating IGF1 (P= 3× 10− 5; Supplementary
Figure 2). A strong inverse relationship was observed between the
methylation of 8/8 CGs of the P2 promoter and growth accelera-
tion in response to GH administration (Supplementary Table 4).
Again, the correlation was maximal for CG-137 methylation
(P= 2.7 × 10− 10; Figure 3a and Supplementary Figure 1a), which
accounted for ~ 25% of the variability in the response to GH. We
conﬁrmed this ﬁnding by building a general linear model for
regression of age, sex, GH dose and CG-137 methylation on
growth rate increment (Table 2). Comparable patterns of correla-
tion were found for the increase in serum IGF1 (P= 1.7 × 10− 10 for
CG-137; Figure 3b and Supplementary Figure 1b, Supplementary
Table 5).
DISCUSSION
The consistency and statistical strength of the observed correla-
tions support that the CG methylation of the P2 promoter of the
IGF1 gene is a major determinant of the individual response to GH
treatment across children with idiopathic short stature. The effect
size of this association is comparable with the association
previously reported between growth rate response and the
common GH receptor d3 deletion variant.2 Furthermore, our
observations suggest that the epigenetic association reported
herein has functional relevance since methylation of CG-137, as
well as methylation of the other CGs of the P2 promoter, is
associated with the transcriptional effects initiated at the P2
promoter following GH injection. Mice models have revealed that
GH effects on skeletal growth are mediated by IGF1 produced
in situ by growth plate chondrocytes, not by circulating IGF1.25
Like other studies before,26 we found a strong correlation
Figure 1. Schematic representation of the human IGF1 gene with its two promoters (P1, P2). The three closest Stat5b binding sites are
ﬁgured as black triangles ( ). The studied CGs are shown as lollypops within the two promoters. Mean methylation levels are ﬁgured as
( 475%; 40-75%; o20%). TSS are shown as broken arrows. The horizontal bar encompasses the eight CGs that show the strongest
association with response to GH.
Table 2. General linear model for regression of sex, age, GH dose and CG-137 methylation on increment in growth rate (cm per year) induced by GH
treatment
Estimates s.e. t-value Pr(4|t|)
Intercept 13.21 1.7 7.8 2 × 10-12
Age at GH onset (years) 0.13 0.05 2.46 0.015
Sex 0.03 0.28 0.12 0.91
GH dose (mg kg− 1 per week) 0.014 6.7 × 10− 3 2.04 0.04
CG-137 methylation (%) − 0.22 0.032 − 6.8 4 × 10−10
Figure 2. (a) CG-137 methylation correlates negatively with the
increment in serum IGF1 after the ﬁrst GH injection (N= 40; R=− 0.7,
P= 3.4 × 10− 7); (b) CG-137 methylation correlates negatively with
the increment in P2-driven IGF1 transcripts in PBMC in response to
acute GH injection in 40 children (R=− 0.82, P= 5 × 10− 11).
IGF1 promoter methylation
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between the increase in height and the increase in circulating
IGF1. As circulating IGF1 originates mostly in the liver,27 the latter
correlation suggests that the GH-induced levels of IGF1 expression
in liver and chondrocytes are proportional in a given individual,
and could share some of the epigenetic regulation reported in the
current study.
Clearly however, a weakness of our study is that we could not
study the association of P2 methylation with transcription or GH
responsiveness in liver and growth plates, the physiological tissues
regulating GH effects on IGF1 production and skeletal growth.
Hepatocytes and chondrocytes have their own epigenome. Such
lack of availability and analysis of epigenomes in speciﬁc cells
of physiological tissues is a common but major limitation of
epigenetic epidemiology,28–30 which most often has to rely on
blood cells. Herein the observations made in PBMC can only be
extrapolated to liver and growth plate through physiological
speculation.
Other questions left unanswered include the molecular
mechanisms taking place at the P2 promoter locus under GH
effect and correlating CG methylation with the regulation of gene
transcription. This correlation was observed in the mononuclear
blood cells of our patients following the ﬁrst GH injection. Liver
expression of the IGF1 gene is mainly controlled at the
transcriptional level by GH from the pituitary.31 In mammals
including humans, the IGF1 gene is composed of six exons and
ﬁve introns that span480 kb of chromosomal DNA32,33 which are
located in 12q23.2 in humans. Tandem promoters direct IGF1 gene
transcription through unique leader exons. Promoter 1, which uses
heterogeneous transcription initiation sites, is active in multiple
animal tissues,34 while the smaller and simpler promoter 2 is
primarily but not exclusively active in the liver of cattle,19 unlike in
rodents where promoter 2 activity seems exclusively hepatic.14
Although the biochemical mechanisms responsible for different
tissue-speciﬁc patterns of IGF1 promoter activity are unknown, the
DNA sequences of both proximal promoters are relatively well-
conserved in mammals based on analyses of available genomic
databases (74% over 420 nucleotides for promoter 1, 58% over
404 nucleotides for promoter 2 between rat and human IGF1),14
suggesting that functional properties of each promoter have been
maintained during speciation as essential aspects of the biology of
IGF1 gene regulation.14 GH exerts its effects through the JAK/Stat
pathway with the translocation of activated Stat5b transcription
factor to the nucleus where it regulates IGF1 transcription.18
Recent results suggest that GH-induced Stat5 activation of IGF1
gene expression in mouse liver might be collectively mediated
by at least eight Stat5 binding sites located in distal intronic and
5′-ﬂanking regions of the IGF1 gene, distantly from the IGF1
promoter.35 The identiﬁcation of multiple distal Stat5 binding sites
underscores the complexity of the mechanism that mediates GH
regulation of IGF1 gene expression. Active Stat5b interacts with
multiple DNA binding sites in chromatin within the IGF1 locus, and
through mechanisms not yet characterized, promotes the rapid
transmission of information to the two IGF1 promoters, culminat-
ing in induction of IGF1 gene transcription and production of IGF1
mRNAs and protein.14 In the liver of hypophysectomised rats, GH
induces dramatic changes in chromatin at the IGF1 locus and
activates IGF1 transcription by distinct promoter-speciﬁc epige-
netic mechanisms.17,36 The proximal part of rat P2 is an important
site of transcriptional regulation by GH via Stat5b.14 In rat liver, GH
induces rapid and dramatic changes in chromatin at the P2
promoter and activates IGF1 transcription by speciﬁc epigenetic
mechanisms.17,36 At promoter P2, GH facilitates recruitment then
activation of RNA Pol II to initiate transcription, whereas at
promoter P1, GH causes RNA Pol II to be released from a
previously recruited poised and paused pre-initiation complex.17
These recent advances on epigenetic mechanisms involving
chromatin landscape in rodent liver,17 as well as our observation
of a relationship between DNA methylation variation and IGF1
transcripts in PBMC, provide an impetus to address fundamental
mechanistic questions that will help decipher the epigenetic
regulation of IGF1 gene expression in baseline conditions and in
response to GH. Yet, not only CG location and composition are
different in human and rat IGF1 promoters (personal observation)
but the pattern of methylation and its transcriptional effects on rat
promoters are still unknown.
To our knowledge, the current study offers the ﬁrst clinical
evidence of a link between DNA methylation and the response to
a treatment in humans, illustrating the role of epigenetic variation
as a potent contributor to personalized therapeutics.
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